Summary p53 gene aberrations are common in human malignancies, and recent studies suggest that in cervical carcinoma p53 function is inactivated either by complex formation with human papillomavirus (HPV) E6 product or by gene mutation. Using polymerase chain reaction (PCR) followed by denaturing gradient gel electrophoresis (DGGE), we examined the mutational status of the four 'hotspot' regions of the p53 gene in 47 primary cervical carcinomas. HPV status was determined, also by PCR. In 20 of these cases, we examined for loss of heterozygosity (LOH) on chromosome l7pl3. In the 47 carcinomas, and in a further 68 biopsy specimens from normal, premalignant and malignant cervix, we investigated aberrant immunocytochemical expression of p53. Immunocytochemically, abnormal p53 expression was detected in 13 of 115 cases (8/57 carcinomas). Somatic mutation in p53 was detected in 1 of 47 cervical carcinomas; 36 were positive for HPV 16, 18 or 33. A low level of allele loss (3 out of 20 cases) was detected on chromosome 17p, occurring in both HPV-positive and HPV-negative cases, and in cases with and without p53 mutations. We conclude that somatic mutation in the hotspot regions of the p53 gene occurs infrequently in cervical carcinomas; that immunocytochemically detectable levels of p53 are also infrequent; and that there is no consistent correlation between p53 mutational status, LOH on chromosome 17p or HPV status in these cancers.
Loss of function of the p53 tumour-suppressor gene has now been implicated in a wide variety of human malignancies. For example, allele losses on the short arm of chromosome 17 in the region of the p53 gene (17pl3.1) have been demonstrated in 60% of breast carcinomas (Mackay et al., 1988; Devilee et al., 1989) , 50-60% of ovarian epithelial carcinomas (Eccles et al., 1990; Russell et al., 1990) , over 70% of osteosarcomas (Toguchida et al., 1989) , 55% of astrocytomas (Fults et al., 1989) , 63% of bladder carcinomas (Tsai et al., 1990) , 75% of colonic carcinomas (Vogelstein et al., 1988) and up to 100% of small-cell lung carcinomas (Mori et al., 1989) . Somatic mutations in the p53 gene have also been found in a substantial proportion of tumour types, and these may or may not be associated with allele losses in the region of p53 on chromosome 17p (Nigro et al., 1989; Chiba et al., 1990; Eccles et al., 1992) . Over 80% of the somatic mutations identified in the p53 gene have been found to cluster in four 'hotspot' regions A-D (HSRs A-D), that coincide with the evolutionarily most highly conserved regions of the gene (Nigro et al., 1989) .
Monoclonal antibodies have been developed for the detection of p53 gene products by immunocytochemical means, using frozen or formalin-fixed paraffin-embedded tissues (Banks et al., 1986; Midgley et al., 1992; Vojtesek et al., 1992) . As the half-life of the wild-type protein is extremely short, and the stability of the mutant form is increased, it is generally assumed that any p53 product detected immunohistochemically represents the mutant form (Lane & Benchimol, 1990) . False positives, resulting from non-mutational stabilisation of the protein, and possibly involving interruption to the normal degradative pathway, have been identified in cell lines (Wynford-Thomas, 1992) , but the incidence of such genuine false positives in human tumours is not yet clear.
Only a few studies have examined the status of p53 in cervical carcinoma, but recent data have suggested it may have an important role (Crook et al., 1991a (Crook et al., , 1992 Fujita et al., 1992; Kaelbling et al., 1992) . There are plausible theoretical grounds for the proposition that p53 alterations may act in combination with human papillomaviruses (HPV), which have long been associated with cervical carcinogenesis (Bosch & Munoz, 1989; zur Hausen, 1989) . The HPV E6-and E7-encoded oncoproteins are believed to form complexes with the products of p53 and Rb genes respectively (Banks et al., 1990; Scheffner et al., 1991) , conferring growth advantage through inhibition of p53 (and Rb) activity (O'Rourke et al., 1990) . The formation of complexes between HPV E6 and p53 proteins has been shown, in vitro, to result in targeting of p53 for degradation, through a ubiquitin-dependent proteolysis system (Scheffner et al., 1991) , and hence to low levels of p53 protein (perhaps not immunocytochemically detectable) in the cell. Interaction between p53 and HPV 16 E7 has also been demonstrated, in studies showing that expression of wild-type p53 suppresses the immortalising activity of HPV 16 E7, whereas mutated murine p53 potently enhances its transforming activity in rodent systems (Crook et al., 1991b) .
Sequencing of p53 DNA and mRNA, from cervical carcinoma tissue and cell lines respectively, revealed wild-type p53 in those that were HPV positive, whereas the mutated form was demonstrated only in those that were HPV negative (Crook et al., 1991a (Crook et al., , 1992 . This led to the suggestion that inactivation of p53 function, either by mutation or by complexing with HPV gene product, is central to carcinogenesis in the cervix.
In this study, we have examined p53 function by three principal techniques. Firstly, we screened for the presence of aberrant p53 expression in 115 cervical biopsy specimens (including 57 invasive carcinomas) using an immunohistochemical technique. Secondly, in 47 of the 57 carcinomas, we investigated the incidence of mutations in the four recognised mutational 'hotspots' A-D and in a fifth region encoding amino acids 193-218 of the p53 gene, using a combined polymerase chain reaction (PCR)/denaturing gradient gel electrophoresis (DGGE) technique (Sheffield et al., 1989; Borresen et al., 1991 informed consent for its use in this study. Specimens of tumour tissue were 'snap frozen' in liquid nitrogen. Cryostat sections were cut for haematoxylin and eosin staining to confirm tumour presence, and non-neoplastic tissue was trimmed from the frozen tissue block before DNA extraction. Blocks which included less than 70% neoplastic cells were not used for DNA extraction. Fixed specimens were obtained from the archives of the Edinburgh University Pathology Department.
p53 immunocytochemistry Four-micron sections from 115 cervical biopsy specimens (including 57 invasive cervical carcinomas), fixed in either formalin or periodate-lysine-paraformaldehyde-dichromate (PLPD) (Pollard et al., 1987) , and histologically distributed as in Table I were used. An avidin-biotin (AB) complex method was employed, with human p53-specific mouse monoclonals PAb 1801 (Cambridge Bioscience) and MAb DO-7 (a gift from Professor D. Lane, CRC Laboratories, Dundee, UK) as primary antibodies. Both antibodies recognise wild-type and mutated p53 but recognise different epitopes. The epitope recognised by PAb 1801 probably lies between amino acids 1 and 91 of the p53 protein, while that recognised by MAb DO-7 lies between amino acids 1 and 45, and probably between amino acids 37 and 45 . Biotinylated rabbit anti-mouse antiserum (1:250) was used as secondary antibody, AB complex as final stage, and diaminobenzidine for visualisation. PAb 1801 (1:100) was used on PLPD-fixed tissue only; MAb DO-7 (1:250 formalin fixed; 1:1,000 PLPD fixed) was used on all specimens. In each run, a section of a colonic adenocarcinoma known from previous sequencing experiments to contain a mutation of the p53 gene was included as a positive control. For each case, negative control sections were made in which primary antibody was omitted but all other steps performed as for test sections.
Analysis ofp53 mutations
The GC-clamped PCR primers and the method used to amplify across the 'hotspot' regions A-D (codons 128-153, 155-185, 237-253 and 265-301 respectively) of the p53 gene were modified in the following ways from those previously described by Borresen et al. (1991) : 500 ng of cervical tumour DNA was used as template in 100 ll reactions; a fifth pair of GC-clamped primers (for convenience designated the 'E' primers) was used to amplify the non-primer region corresponding to codons 193-218 of exon 6. PCR products from 47 cervical carcinomas (a sUbset of the 57 included in the p53 immunocytochemical analysis) were subjected to electrophoresis on 3% agarose gels containing ethidium bromide; and the presence of amplified product was confirmed by UV transillumination of the gel. Products were then screened for p53 mutations by parallel DGGE (30-80% denaturing gradient polyacrylamide/55°C) with those from previously sequenced ovarian and colonic carcinomas, known to possess p53 mutations in regions A, B, C, D or E, as positive controls. Detected mutations were characterised by conventional DNA sequencing of PCR products amplified from the tumour and corresponding constitutional (blood) DNA.
Allele loss analysis Six polymorphic DNA probes were radiolabelled and used in restriction fragment length polymorphism (RFLP) analysis to compare tumour and constitutional genotypes of 20 cervical carcinoma patients, for detection of LOH, as previously described (Busby-Earle et al., 1993) . Aliquots of 10 jig of paired tumour/blood DNA samples were digested with appropriate restriction endonucleases, size fractionated on 0.8% agarose gels, and Southern blotted onto Hybond-N membranes, which were used in hybridisation reactions (65°C/16 h), prior to autoradiography, as previously described (Busby-Earle et al., 1993) . These 20 cases formed a subset of the 47 cases analysed for p53 mutations, described above.
HPV analysis
The method used has been detailed elsewhere (Busby-Earle et al., 1993) . Briefly, primers specific for the E6 gene of HPV 6, 11, 16, 18 and 33 (Arends et al., 1991) were used to set up standard 100 ,lI PCR reactions, containing 500 ng of template (cervical carcinoma DNA) and 2.5 pl of Taq polymerase (Northumbria Biologicals). Thirty-two to thirty-five cycles of denaturation (94°C) (1 min), annealing (55°C for HPV 6/16 or 50°C for HPV 11/18/33) (2 min) and extension (72C) (3 min) were preceded by a 1.5 min denaturation and ended with a 10 min extension. Products were detected as described above for p53. Plasmids containing the appropriate HPV sequence were used as positive controls; and the labelled insert was used in Southern blotting analyses to detect the integrated or episomal status of HPV in 12 specimens.
Results

p53 immunocytochemistry
The two antibodies employed, PAb 1801 and MAb DO-7, produced specific nuclear staining in the positive control colonic carcinoma tissue, while normal colonic mucosa was negative (Figure 1 ). Antibody DO-7 produced superior staining to PAb 1801, being crisper and more intense, although the distribution of positively stained cells was similar.
Positive Of the two cervical carcinomas in which the silent (CGA-* CGG transition) p53 mutation was detected, one was negative for the five HPV types examined, while the other was positive for HPV 16. Of the other ten HPVnegative tumours, in which all five p53 regions had been successfully amplified, only one (the tumour in which a CGC-.*TGC transition was detected in HSR B) revealed p53 mutation on DGGE screening.
Of the eight cervical carcinomas exhibiting p53 immunocytochemical positivity, four were positive for HPV 16 and one for HPV 18 and three were negative for the various HPV types tested.
Discussion
In this study, we investigated p53 gene alterations in primary cervical carcinomas using three different approaches: mutational status of the p53 gene; LOH at the p53 gene locus on chromosome 17p; and demonstration of aberrant immunocytochemical expression of p53 in tissue sections. We sought correlations between p53 alterations and HPV status of tumours.
Immunocytochemical detection of p53 protein was infrequent both in cervical carcinoma and in its preinvasive phases. This contrasts with reported findings in a range of other common tumours (Bartek et al., 1991) , especially breast (Cattoretti et al., 1988) , lung (Iggo et al., 1990) , ovary (Eccles et al., 1992) , colon (Purdie et al., 1991) and skin (L. Stark, personal communication), in which high levels of p53 protein expression are common. In breast (Davidoff et al., 1991) and endometrial (Kohler et al., 1992) carcinoma, a good correlation has been found between p53 expression and advanced disease. In this series, positive nuclear staining was present in only 13 out of 115 cervical biopsies (8 of 57 carcinomas), and was sparse in comparison with positive controls. Staining occurred in benign, premalignant and malignant lesions, and rather than indicating mutation in the p53 gene its presence may reflect increased p53 expression in cells undergoing DNA repair (Lane, 1992) .
A further distinction from other common solid tumours was the frequency with which mutations were found in 'hotspot' regions of the p53 gene. Out of 47 invasive cervical carcinomas analysed, only one somatic mutation (in an HPVnegative tumour) was found in the four mutationally active 'hotspot' regions. The mutation occurred at codon 175, resulting in an arginine + cysteine transition, which has not previously been reported at this codon (Caron de Fromentel & Soussi, 1992) . In two other cervical carcinomas (one HPV 16 positive and the other HPV negative), the apparent mutations detected in the 'E' region were also present in the corresponding constitutional DNA samples. On sequencing these were each found to be silent mutations at codon 213, thus constituting a normal polymorphism. It is notable that in 9 out of the 11 HPV-negative cervical carcinomas, no mutations were detected in any of the five p53 regions examined.
The technique of constant denaturing gradient gel electrophoresis (Borresen et al., 1991 ) is a rapid and reliable method of screening for mutations in the 'hotspot' regions of the p53 gene, and detected all mutations present in positive controls with no false positives. Regions A-E examined in this study cover 89% of the mutations which have so far been detected (Caron de Fromentel & Soussi, 1992) . It is possible that by screening a wider area of the gene a few more mutations might have been demonstrated, but in studies of cervical carcinomas and derived cell lines in which the entire coding region of the p53 gene has been sequenced the mutations found have only occurred in regions A-D (Crook et al., 1991b (Crook et al., , 1992 . Our findings were in agreement with those recently reported by Helland et al. (1993) , who, using a similar technique, found only two mutations of the p53 gene (one of which was silent) in a series of 92 cervical carcinomas.
Although not every mutation in the p53 gene may lead to accumulation of the protein (Wynford-Thomas, 1992) , it has been suggested that if p53 protein is demonstrated immunohistochemically it is likely to be mutant (Lane & Benchimol, 1990) . In this series in which extremely sparse p53 expression in a minority (8/47) of cases was observed, there was a virtual absence of p53 mutations in the four HSRs. However, in the single carcinoma in which a somatic mutation did occur, sparse p53 protein expression was observed with antibody MAb DO-7. In the two tumours with silent mutations at codon 213, one showed similar sparse accumulation of p53 protein product while the other did not. Therefore, in this series, no clear-cut correlation could be demonstrated between immunocytochemical detection of p53 and the occurrence of p53 mutations.
In other neoplasms, mutation in one p53 allele is fre-quently accompanied by loss of the corresponding normal allele (Baker et al., 1990; Iggo et al., 1990; Prosser et al., 1990; Eccles et al., 1992) . By contrast, the cervical carcinomas in this series showed a relatively low frequency of LOH on chromosome 17p (15%), within the range expected as 'background' for any gene locus examined, and in keeping with the relative absence of p53 mutations. Moreover, in the three cases showing allele loss, no mutations were detected in the remaining allele in the four 'hotspot' regions suggesting these may have occurred as a consequence of the general genetic instability exhibited by many tumours. These findings are in keeping with those of Helland et al. (1993) , who reported allelic imbalance in 11 out of 52 informative cases (22%) at the p53 locus.
Other recent studies have suggested that inactivation of p53 function is fundamental to cervical carcinogenesis (Crook et al., 1991a (Crook et al., , 1992 . It has been proposed that inactivation of the gene product may occur either by p53 gene mutation in HPV-negative tumours, or by complexing with the HPV E6 transforming gene product in HPV-positive tumours. In our studies, only 1 of 11 HPV-negative carcinomas showed evidence of a somatic mutation in any of the four mutational 'hotspots' of the p53 gene. However, we screened only for HPV types 16, 18 and 33, most commonly associated with cervical cancer, and we cannot exclude the possibility that some negative cases may have been positive for other less common high-risk virus types. Our findings are consistent with those of Helland et al. (1993) , who found no mutations in the p53 gene in all four of their HPV-negative patients.
If increased p53 expression in benign, premalignant and malignant lesions reflects DNA repair, it is surprising that it was so rarely observed. Inactivation of p53 may occur by interaction with the HPV E6 gene product, and it is possible that elevated expression of p53 detected immunocytochemically in HPV-positive tumours could reflect lack of E6 gene expression in these tumours. Other possible mechanisms of p53 inactivation such as alteration in mdm-2 gene expression have not been addressed in this study. The product of the mdm-2 oncogene binds wild-type p53 in vitro (Oliner et al., 1992) , and it is possible that its increased expression may account for p53 accumulation in our immunocytochemically positive cases.
Overall, our findings suggest that cervical carcinoma differs from other common neoplasms in the manner in which p53 gene alterations are involved in the carcinogenic process. Mutations in the highly conserved regions of the gene are relatively infrequent and no correlation has been found between p53 mutational status and either LOH on chromosome 17p or the presence or integration of HPV 16, 18 or 33. Finally, the immunohistochemical demonstration of p53 is not a striking feature in the preinvasive or invasive phases of the malignancy.
